Matrixyl vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Matrixyl is the most widely used collagen-stimulating cosmetic peptide. As a matrikine — a fragment of type I procollagen — it signals skin cells to synthesize new collagen, elastin, and fibronectin, reducing wrinkle depth and improving skin firmness and elasticity.
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- N/A — topical; sustained signaling effects on fibroblasts persist beyond single application
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 3–8% concentration
- 10 mg per day
- Frequency
- Once or twice daily
- Daily for 10–30 days
- Key Benefits
- Stimulates collagen I, III, and IV synthesis
- Increases fibronectin and glycosaminoglycan production
- Reduces wrinkle depth and length by 27–68% (studies)
- Improves skin firmness and elasticity
- Reduces dark circles and undereye bags
- Synergistic with retinol, vitamin C, and growth factors
- Suitable for all skin types including sensitive
- Well-studied with published clinical data
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Exceptional safety profile
- Non-irritating, suitable for sensitive skin
- No known adverse effects at cosmetic concentrations
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —